← All trials
NCT05387954
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 1, 2022
- Primary completion
- Jun 1, 2030
- Completion date
- Jun 1, 2030
- First posted
- May 24, 2022
- Last posted
- May 24, 2022
- Enrollment
- 792
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Assistance Publique - Hôpitaux de ParisLead sponsor
- AbbottCollaborator
- Centre Hospitalier St AnneCollaborator
- University of ParisOverall official - principal investigator
- Hôpital Européen Georges-PompidouStudy director
- Government of FranceCollaborator
- W.L.Gore & AssociatesCollaborator
- University of ParisOfficial
- Hôpital Européen Georges-PompidouOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.